NUTX Stock Analysis: Nutex Health | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 1.430m USD | 12M Return: 126.8% | US67079U3068 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.6M
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nutex Health Inc. (NUTX) is a Houston-based healthcare services company operating in the United States through three business segments. Its Hospital segment runs a network of micro hospitals, specialty hospitals, and hospital outpatient departments providing emergency, inpatient, and behavioral health care, along with imaging, laboratory, and pharmacy services. The Population Health Management (PHM) segment offers management, administrative, and technology support to affiliated hospitals and physician groups, including the operation of independent physician associations (IPAs) supported by a cloud-based platform. The Real Estate segment owns and leases the land and buildings used by the companys hospital facilities. The company was founded in 2011 and listed on NASDAQ in April 2022.
The micro hospital model used by Nutex is a smaller-scale alternative to traditional acute-care hospitals, typically designed to serve communities that lack convenient access to full-service facilities, often operating with limited inpatient beds and a focus on emergency and outpatient services. In the broader healthcare sector, population health management has grown as providers and payers seek to coordinate care across networks, improve outcomes, and reduce costs through value-based arrangements rather than purely fee-for-service billing.
- Micro hospital patient volumes and reimbursement rates drive segment revenue
- PHM segment scales via new IPA contracts and platform adoption
- Real estate holdings and capital allocation pressure balance sheet liquidity
| Net Income: 179.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 18.53 > 1.0 |
| NWC/Revenue: 55.32% < 20% (prev 35.11%; Δ 20.21% < -1%) |
| CFO/TA 0.29 > 3% & CFO 279.6m > Net Income 179.9m |
| Net Debt (449.8m) to EBITDA (384.3m): 1.17 < 3 |
| Current Ratio: 5.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.02m) vs 12m ago 6.46% < -2% |
| Gross Margin: 51.26% > 18% (prev 51.35%; Δ -0.09% > 0.5%) |
| Asset Turnover: 93.79% > 50% (prev 94.19%; Δ -0.41% > 0%) |
| Interest Coverage Ratio: 18.37 > 6 (EBIT TTM 363.3m / Interest Expense TTM 19.8m) |
| A: 0.49 (Total Current Assets 585.6m - Total Current Liabilities 117.2m) / Total Assets 964.6m |
| B: -0.18 (Retained Earnings -173.5m / Total Assets 964.6m) |
| C: 0.40 (EBIT TTM 363.3m / Avg Total Assets 902.8m) |
| D: 0.86 (Book Value of Equity 394.3m / Total Liabilities 457.3m) |
| Altman-Z'' = 6.21 = AAA |
| DSRI: 0.94 (Receivables 356.7m/355.0m, Revenue 846.7m/792.2m) |
| GMI: 1.00 (GM 51.35% / 51.26%) |
| AQI: 0.79 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.07 (Revenue 846.7m / 792.2m) |
| TATA: -0.10 (NI 179.9m - CFO 279.6m) / TA 964.6m) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of September 26, 2026, the stock is trading at USD 220.11 with a total of 208,854 shares traded. Over the past week, the price has changed by +5.42%, over one month by +17.02%, over three months by +47.62% and over the past year by +126.75%.
Current recommended Stop Loss: 191.20 (which is 13.1% or 2.7 ATR below the current price).
Nutex Health has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy NUTX.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 283 | 28.6% |
P/E Trailing = 8.0926
P/S = 1.6886
P/B = 3.6192
Revenue TTM = 846.7m USD
EBIT TTM = 363.3m USD
EBITDA TTM = 384.3m USD
Long Term Debt = 31.1m USD (from longTermDebt, last quarter)
Short Term Debt = 18.1m USD (from shortTermDebt, last quarter)
Debt = 655.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 307.6m
Net Debt = 449.8m USD (calculated: Debt 655.0m - CCE 205.2m)
Enterprise Value = 1.88b USD (1.43b + Debt 655.0m - CCE 205.2m)
Interest Coverage Ratio = 18.37 (Ebit TTM 363.3m / Interest Expense TTM 19.8m)
EV/FCF = 6.86x (Enterprise Value 1.88b / FCF TTM 274.2m)
FCF Yield = 14.59% (FCF TTM 274.2m / Enterprise Value 1.88b)
FCF Margin = 32.38% (FCF TTM 274.2m / Revenue TTM 846.7m)
Net Margin = 21.25% (Net Income TTM 179.9m / Revenue TTM 846.7m)
Gross Margin = 51.26% ((Revenue TTM 846.7m - Cost of Revenue TTM 412.7m) / Revenue TTM)
Gross Margin QoQ = 67.04% (prev 42.37%)
Tobins Q-Ratio = 1.95 (Enterprise Value 1.88b / Total Assets 964.6m)
Interest Expense / Debt = 3.02% (Interest Expense 19.8m / Debt 655.0m)
Taxrate = 20.67% (71.0m / 343.5m)
NOPAT = 288.2m (EBIT 363.3m * (1 - 20.67%))
Current Ratio = 5.00 (Total Current Assets 585.6m / Total Current Liabilities 117.2m)
Debt / Equity = 1.66 (Debt 655.0m / totalStockholderEquity, last quarter 394.3m)
Debt / EBITDA = 1.17 (Net Debt 449.8m / EBITDA 384.3m)
Debt / FCF = 1.64 (Net Debt 449.8m / FCF TTM 274.2m)
Total Stockholder Equity = 346.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.93% (Net Income 179.9m / Total Assets 964.6m)
RoE = 51.88% (Net Income TTM 179.9m / Total Stockholder Equity 346.8m)
RoCE = 96.14% (EBIT 363.3m / Capital Employed (Equity 346.8m + L.T.Debt 31.1m))
RoIC = 35.01% (NOPAT 288.2m / Invested Capital 823.2m)
WACC = 7.99% (E(1.43b)/V(2.08b) * Re(10.55%) + D(655.0m)/V(2.08b) * Rd(3.02%) * (1-Tc(0.21)))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 72.61 | Cagr: 20.73%
[DCF] Terminal Value 77.97% ; FCFF base≈197.8m ; Y1≈226.7m ; Y5≈333.7m
[DCF] Fair Price = 667.6 (EV 5.02b - Net Debt 449.8m = Equity 4.57b / Shares 6.85m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.74 | # QB: 0
Revenue Correlation: 94.16 | Revenue CAGR: 84.51% | SUE: -0.05 | # QB: 0
EPS current Quarter (2026-09-30): EPS=5.71 | Chg30d=+13.80% | Revisions=+62% | Analysts=5
EPS current Year (2026-12-31): EPS=27.79 | Chg30d=+29.15% | Revisions=+62% | GrowthEPS=+165.2% | GrowthRev=-0.4%
EPS next Year (2027-12-31): EPS=27.87 | Chg30d=+21.02% | Revisions=+62% | GrowthEPS=+0.3% | GrowthRev=+10.6%
[Analyst] Revisions Ratio: +83% (up=15, down=0)